
China Pharma Holdings, Inc.
CPHIAMEXHealthcareDrug Manufacturers - Specialty & Generic
常规交易时段
US$0.95
−US$0.03 · -3.06%
CPHI公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Sell
Trim exposure — unfavorable risk-reward
估值
27
Expensive
动量
24
Weakening
情绪
52
Mixed
风险韧性
27
High Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
- 行业
- Drug Manufacturers - Specialty & Generic
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Zhilin Li
- 上市以来
- 2002年4月17日
- 雇员
- 215
市场位置
日内区间
当前US$0.95,
52周区间
当前US$0.95,
- 开盘价
- US$0.99
- 前收盘价
- US$0.98
- 成交量
- 11.57万
- 0.03× 平均值
- 平均成交量
- 444.28万
- 日均成交量
- 市值
- 3849.59万 USD
- 贝塔
- 1.07
- 市场参考 1
- 50天平均值
- US$1.1114
- 低于平均水平-14.52%
- 200天平均值
- US$1.0096
- 低于平均水平-5.90%
财报历史与展望
- 最新每股收益结果
- -0.04
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
CPHI同业公司
继续GoAI的研究
在 GoAI 中研究CPHIresearch.disclaimer





